Q1 FY2026 revenue rose to KRW 36.7 billion, with net income at KRW 11.7 billion and strong growth in the Bio-Chemical segment. Major investments in new production capacity and ongoing clinical trials support future growth, while risk management and dividend policies remain robust.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.